These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1346724)

  • 21. Buspirone, 8-OH-DPAT and ipsapirone: effects on hippocampal cerebellar and sciatic fiber excitability.
    Hiner BC; Mauk MD; Peroutka SJ; Kocsis JD
    Brain Res; 1988 Sep; 461(1):1-9. PubMed ID: 2906267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT1A agonists uncouple noradrenergic somatodendritic impulse flow and terminal release.
    Broderick PA; Piercey MF
    Brain Res Bull; 1991 Nov; 27(5):693-6. PubMed ID: 1684526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone.
    Eison AS; Eison MS; Stanley M; Riblet LA
    Pharmacol Biochem Behav; 1986 Mar; 24(3):701-7. PubMed ID: 2871564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo.
    Sharp T; McQuade R; Bramwell S; Hjorth S
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Oct; 348(4):339-46. PubMed ID: 7904048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticonflict effects of acute and chronic treatments with buspirone and gepirone in rats.
    Yamashita S; Oishi R; Gomita Y
    Pharmacol Biochem Behav; 1995 Mar; 50(3):477-9. PubMed ID: 7617689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of apomorphine upon local cerebral glucose utilization in conscious rats and in rats anesthetized with chloral hydrate.
    Grome JJ; McCulloch J
    J Neurochem; 1983 Feb; 40(2):569-76. PubMed ID: 6822839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of 5-HT1A receptor binding sites following chronic treatment with ipsapirone measured by quantitative autoradiography.
    Fanelli RJ; McMonagle-Strucko K
    Synapse; 1992 Sep; 12(1):75-81. PubMed ID: 1357765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the putative anxiolytic SM-3997 on central monoaminergic systems.
    Tatsuno T; Shimizu H; Hirose A; Tanaka H; Kumasaka Y; Nakamura M
    Pharmacol Biochem Behav; 1989 Apr; 32(4):1049-55. PubMed ID: 2572002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
    Pruus K; Skrebuhhova-Malmros T; Rudissaar R; Matto V; Allikmets L
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 2):833-46. PubMed ID: 11220492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buspirone, ipsapirone and 1-(2-pyrimidinyl)-piperazine decrease cold-induced thyrotropin secretion in rats.
    Broqua P; Baudrie V; Bluet-Pajot MT; Chaouloff F
    Eur J Pharmacol; 1991 Nov; 204(2):141-7. PubMed ID: 1687218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for a postsynaptic action of the serotonergic anxiolytics: ipsapirone, indorenate and buspirone.
    Fernández-Guasti A; López-Rubalcava C; Pérez-Urizar J; Castañeda-Hernández G
    Brain Res Bull; 1992 Apr; 28(4):497-501. PubMed ID: 1352175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditioned taste aversion and place preference with buspirone and gepirone.
    Neisewander JL; McDougall SA; Bowling SL; Bardo MT
    Psychopharmacology (Berl); 1990; 100(4):485-90. PubMed ID: 2320709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.
    Li Q; Rittenhouse PA; Levy AD; Alvarez Sanz MC; Van de Kar LD
    Neuropharmacology; 1992 Oct; 31(10):983-9. PubMed ID: 1359439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors.
    J Clin Psychopharmacol; ; . PubMed ID: 1973941
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.